A Study of Surgical Interventions in Fistulizing Conditions

NCT ID: NCT04940611

Last Updated: 2025-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

750 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-05

Study Completion Date

2026-05-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, participants with complex fistulizing conditions will be treated with surgical interventions according to their clinic's standard practice.

The aim of the study is to generate real-world evidence on standard of care for surgical interventions and related outcomes when treating complex fistulizing conditions.

The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-interventional, prospective study of participants with complex fistulizing conditions (CPF-CD, CD develops CD-RVF and CCF) who are currently undergoing surgical intervention in the real world clinical setting.

The study will enroll approximately 750 participants. The data will be collected prospectively at the study sites and will be recorded into electronic data capture forms (EDCs). Participants will be enrolled to the following observational cohorts:

* Participants With CPF-CD
* Participants With CD-RVF
* Participants With CCF

This multi-center study will be conducted in the United States, Canada, Europe, and Israel. Participants undergoing surgical interventions to treat fistulas will be enrolled from surgical and gastrointestinal (GI) specialty sites. The overall duration of the study will be 24 months. Data will be collected at baseline with follow-up information collected approximately every 3 to 6 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohns Disease Fistula Rectovaginal Fistula Complex Perianal Fistula Complex Cryptoglandular Fistula

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants With CPF-CD

Participants diagnosed with CPF-CD will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.

No interventions assigned to this group

Participants With CD-RVF

Participants diagnosed with CD-RVF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.

No interventions assigned to this group

Participants With CCF

Participants diagnosed with CCF will undergo surgical intervention according to their clinic's standard practice to treat the index fistula, and will be observed prospectively for 24 months post-index surgery.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants with CPF-CD

1. CPF-CD that meets one or more of the following criteria:

* High inter-sphincteric, high trans-sphincteric, extra-sphincteric or supra-sphincteric fistula, or
* Presence of greater than or equal to (\>=) 2 external openings, or
* Associated perianal abscess(es)
2. Physician has made the decision to treat with a specific surgical intervention. Procedures may include:

* Fistulotomy, fistula plug, fibrin glue, advancement flap (AF), ligation of inter-sphincteric fistula tract (LIFT), flap repair, fistulectomy, proctectomy, stem cell therapy, other; and seton for palliative purposes.

Participants with CD-RVF: Rectovaginal fistula per physician diagnosis

1\. Physician has made the decision to treat with a specific surgical intervention. Procedures may include:

* Fistulotomy, fistula plug, fibrin glue, AF, LIFT, flap repair, fistulectomy, proctectomy, stem cell therapy, gracilis muscle interposition/tissue grafts, martius procedure, abdominal procedures, other; and seton use for palliative purposes.

Participants with CCF:

1. Complex cryptoglandular fistula that meets one or more of the following criteria:

* Mid or high trans-sphincteric, or
* Anterior in women, or
* Horseshoe fistula
2. Physician has made the decision to treat with a specific surgical intervention. Procedures may include:

* Fistulotomy, fistula plug, fibrin glue, AF, LIFT, flap repair, fistulectomy, proctectomy, stem cell therapy, other; and seton use for palliative purposes

Exclusion Criteria

Participants who meet any below mentioned criterion among CPF-CD, CD-RVF, and CCF diagnosis will be excluded from the study.

1. Current participation in interventional clinical trials.
2. Has CPF-CD: fistula connection to bladder or another organ
3. Has CCF: diagnosis of Inflammatory Bowel Disease (IBD), including Ulcerative Colitis, and Crohn's Disease (CD).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Takeda

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Study Director

Role: STUDY_DIRECTOR

Takeda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cedars-Sinai Medical Center

Los Angeles, California, United States

Site Status

Baptist MD Anderson Cancer Center

Jacksonville, Florida, United States

Site Status

University of South Florida - PARENT

Tampa, Florida, United States

Site Status

University of Kansas Medical Center Research Institute, Inc.

Kansas City, Kansas, United States

Site Status

GI Alliance - Baton Rouge

Baton Rouge, Louisiana, United States

Site Status

Lenox Hill Hospital PRIME

New York, New York, United States

Site Status

UNC Hospitals

Chapel Hill, North Carolina, United States

Site Status

Premier Health

Dayton, Ohio, United States

Site Status

Penn Medicine PA

Philadelphia, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Vanderbilt University Medical Center- GI Endoscopy Lab

Nashville, Tennessee, United States

Site Status

Baylor Research Institute

Dallas, Texas, United States

Site Status

Colon & Rectal Clinic

Houston, Texas, United States

Site Status

AKH - Medizinische Universitat Wien

Vienna, , Austria

Site Status

UZ Antwerpen

Antwerp, , Belgium

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

Jessa Ziekenhuis Hospital

Hasselt, , Belgium

Site Status

Clinique CHC MontLegia

Liège, , Belgium

Site Status

AZ Delta

Roeselare, , Belgium

Site Status

St. Pauls Hospital

Vancouver, British Columbia, Canada

Site Status

Fakultni nemocnice Brno

Brno, , Czechia

Site Status

Fakultni nemocnice u sv. Anny v Brne

Brno, , Czechia

Site Status

NH Hospital a.s.Nemocnice Horovice

Hořovice, , Czechia

Site Status

Fakultni nemocnice Olomouc

Olomouc, , Czechia

Site Status

Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud

Pierre-Bénite, Bouches-du-Rhone, France

Site Status

Fondation Maison Sante Bagatelle

Talence, Gironde, France

Site Status

CHU de Rennes - Hopital Pontchaillou

Rennes, Ille Et Vilaine, France

Site Status

CHRU Hopital Claude Huriez

Lille, Nord, France

Site Status

CHU de Rouen - Hopital Charles Nicolle

Rouen, Seine Maritime, France

Site Status

Groupe Hospitalier Diaconesses - Hopital De La Croix Saint Simon

Paris, , France

Site Status

Hopital Saint Joseph - Paris

Paris, , France

Site Status

Shamir Medical Center (Assaf Harofeh)

Be’er Ya‘aqov, , Israel

Site Status

Rambam Health Care Center

Haifa, , Israel

Site Status

Wolfson Medical Center

Holon, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Istituto Clinico Humanitas

Rozzano, Milano, Italy

Site Status

Amsterdam UMC, Locatie AMC

Amsterdam, , Netherlands

Site Status

UMC Utrecht

Utrecht, , Netherlands

Site Status

Broomfield Hospital

Chelmsford, Essex, United Kingdom

Site Status

Nottingham University Hospital

Nottingham, Nottinghamshire, United Kingdom

Site Status

Royal Victoria Infirmary.

Newcastle upon Tyne, Tyne & Wear, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Canada Czechia France Israel Italy Netherlands United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Alofisel-5007

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LIFT-plug vs LIFT, a RCT Trial
NCT04310800 UNKNOWN NA